Comparing randomized controlled trials and real-world studies in chronic obstructive pulmonary disease pharmacotherapy
DP Tashkin, AN Amin, EM Kerwin - International journal of chronic …, 2020 - Taylor & Francis
Analytic epidemiological studies cover a large spectrum of study methodologies, ranging
from noninterventional observational studies (population-based, case–control, or cohort …
from noninterventional observational studies (population-based, case–control, or cohort …
Comparative effectiveness and safety of LABA-LAMA vs LABA-ICS treatment of COPD in real-world clinical practice
Background Long-acting β 2-agonists (LABAs) and long-acting muscarinic antagonists
(LAMAs) are recommended as initial maintenance treatments for COPD, with their …
(LAMAs) are recommended as initial maintenance treatments for COPD, with their …
Chronic obstructive pulmonary disease exacerbations and pneumonia hospitalizations among new users of combination maintenance inhalers
Importance Clinical guidelines on chronic obstructive pulmonary disease (COPD)
recommend inhalers containing long-acting muscarinic antagonists (LAMAs) and long …
recommend inhalers containing long-acting muscarinic antagonists (LAMAs) and long …
Observational studies of inhaled corticosteroid effectiveness in COPD: lessons learned
Background Randomized controlled trials at times investigate findings suggested by
observational studies. For example, the Towards a Revolution in COPD Health (TORCH) …
observational studies. For example, the Towards a Revolution in COPD Health (TORCH) …
Comparative effectiveness and safety of different types of inhaled long-acting β2-agonist plus inhaled long-acting muscarinic antagonist vs inhaled long-acting β2 …
Background Despite multiple available fixed-dose combinations (FDCs) of inhaled long-
acting β 2-agonists (LABAs) plus long-acting muscarinic antagonists (LAMAs) and LABAs …
acting β 2-agonists (LABAs) plus long-acting muscarinic antagonists (LAMAs) and LABAs …
Comparative effectiveness and safety of generic versus brand-name fluticasone–salmeterol to treat chronic obstructive pulmonary disease
Background: In 2019, the US Food and Drug Administration (FDA) approved the first generic
maintenance inhaler for asthma and chronic obstructive pulmonary disease (COPD). The …
maintenance inhaler for asthma and chronic obstructive pulmonary disease (COPD). The …
Magnolia officinalis L. bark extract and respiratory diseases: From traditional Chinese medicine to western medicine via network target
R Fontana, LB Mattioli, G Biotti, R Budriesi… - Phytotherapy …, 2023 - Wiley Online Library
The understanding of the use of Magnolia officinalis L.(Magnoliaceae) as a possible dietary
supplement for supporting the treatment of airway pathologies might be of clinical interest …
supplement for supporting the treatment of airway pathologies might be of clinical interest …
[HTML][HTML] Effectiveness and safety of COPD maintenance therapy with tiotropium/olodaterol versus LABA/ICS in a US claims database
JK Quint, J Montonen, DB Esposito, X He, L Koerner… - Advances in …, 2021 - Springer
Introduction In patients with chronic obstructive pulmonary disease (COPD), treatment with
long-acting muscarinic antagonist (LAMA)/long-acting β 2-agonist (LABA) combination …
long-acting muscarinic antagonist (LAMA)/long-acting β 2-agonist (LABA) combination …
Risk of Cardiovascular and Cerebrovascular Events in COPD Patients Treated With Long-Acting β2-Agonist Combined With a Long-Acting Muscarinic or Inhaled …
JC Samp, MJ Joo, GT Schumock… - Annals of …, 2017 - journals.sagepub.com
Background: The recent approval of several fixed-dose combination long-acting β2-agonist
(LABA) and long-acting muscarinic antagonist (LAMA) products has increased the use of …
(LABA) and long-acting muscarinic antagonist (LAMA) products has increased the use of …
[HTML][HTML] Evaluating a Cox marginal structural model to assess the comparative effectiveness of inhaled corticosteroids versus no inhaled corticosteroid treatment in …
C Cabrera, C Quélen, M Ouwens, K Hedman… - Annals of …, 2022 - Elsevier
Purpose To evaluate the potential of a Cox marginal structural model (MSM) to estimate the
time-varying causal inference of a known clinical trial association where the effectiveness of …
time-varying causal inference of a known clinical trial association where the effectiveness of …